NeuroBo Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on NeuroBo Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date NeuroBo Pharmaceuticals Inc Strategy Report
- Understand NeuroBo Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
NeuroBo Pharmaceuticals Inc (NeuroBo), formerly Gemphire Therapeutics Inc, is a clinical stage biopharmaceutical company that focuses on developing novel therapeutics for neurodegenerative and cardiometabolic diseases. It has pipeline product candidates include ANA001, an oral niclosamide formulation developed for moderate coronavirus disease (COVID-19 which is phase 2 clinical trials. Gemcabene for the treatment of homozygous familial hypercholesterolemia (HoFH) and hypertriglyceridemia (SHTG) which is a serious medical condition that increases the risk of life-threatening cardiovascular diseases; NB-01 for painful diabetic neuropathy (PDN); and NB-02 treated for neurodegenerative diseases such as Alzheimer's disease and tauopathies. The company has research facilities in South Korea. NeuroBo is headquartered in Boston, Massachusetts, the US.
Headquarters
United States of America
Address
545 Concord Avenue, Suite 210, Cambridge, Massachusetts, 02138
Website
www.neurobopharma.com
Telephone
1 857 7029600
No of Employees
8
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
NRBO (NASD)
EPS
XYZ
Net Income (2022)
XYZ
10.7%
(2022 vs 2021)
Market Cap*
$17.0M
* As of and is in US$
NeuroBo Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline - |
| Gemcabene: homozygous familial hypercholesterolemia (HoFH), hypertriglyceridemia (SHTG) |
| ANA001: Moderate Coronavirus Disease (COVID-19) |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In August, the company entered into an agreement with MThera Pharma Co., Ltd. to continue the development of NB-01 for the treatment of painful diabetic neuropathy to MTHERA. |
| 2023 | New Product Approvals | In May, the company announced FDA clearence for its DA-1241 for the treatment of NASH. |
| 2023 | New Product Approvals | In April, the company announced the submission of IND application the FDA for DA-1241 for the treatment of NASH |
Competitor Comparison
| Key Parameters | NeuroBo Pharmaceuticals Inc | Merck & Co Inc | Pfizer Inc | AstraZeneca Plc | Regeneron Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United Kingdom | United States of America |
| City | Cambridge | Kenilworth | New York | Cambridge | Tarrytown |
| State/Province | Massachusetts | New Jersey | New York | England | New York |
| No. of Employees | 8 | 72,000 | 88,000 | 89,900 | 13,450 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Andrew Koven | Chairman | Executive Board | 2022 | 65 |
| Hyung Heon Kim | President; Director; Chief Executive Officer | Executive Board | 2023 | - |
| Marshall Woodworth | Principal Accounting Officer; Principal Financial Officer; Chief Financial Officer | Senior Management | 2024 | - |
| Michael Salsbury | Director | Non Executive Board | 2019 | 73 |
| D. Gordon Strickland | Director | Non Executive Board | 2022 | 76 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward